Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.

Argiriadi MA, Benatuil L, Dubrovska I, Egan DA, Gao L, Greischar A, Hardman J, Harlan J, Iyer RB, Judge RA, Lake M, Perron DC, Sadhukhan R, Sielaff B, Sousa S, Wang R, McRae BL.

BMC Mol Cell Biol. 2019 Aug 5;20(1):29. doi: 10.1186/s12860-019-0213-4.

2.

Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt.

Gauld S, Jacquet S, Gauvin D, Wallace C, Wang Y, McCarthy R, Goess C, Leys L, Huang S, Su Z, Edelmayer R, Wetter J, Salte K, McGaraughty S, Argiriadi M, Honore P, Luccarini JM, Bressac D, Desino K, Breinlinger E, Cusack K, Potin D, Kort M, Masson P.

J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046. doi: 10.1124/jpet.119.258046. [Epub ahead of print]

3.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

4.

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.

Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1799-1806. doi: 10.1016/j.bmcl.2019.05.015. Epub 2019 May 9.

PMID:
31101472
5.

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).

Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ.

BMC Rheumatol. 2018 Aug 28;2:23. doi: 10.1186/s41927-018-0031-x. eCollection 2018.

6.

Covalent binders in drug discovery.

Vasudevan A, Argiriadi MA, Baranczak A, Friedman MM, Gavrilyuk J, Hobson AD, Hulce JJ, Osman S, Wilson NS.

Prog Med Chem. 2019;58:1-62. doi: 10.1016/bs.pmch.2018.12.002. Epub 2019 Mar 11.

PMID:
30879472
7.

Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.

Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A.

Bioorg Med Chem Lett. 2016 Nov 15;26(22):5562-5567. doi: 10.1016/j.bmcl.2016.09.077. Epub 2016 Oct 11.

PMID:
27789138
8.

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.

Dinges J, Harris CM, Wallace GA, Argiriadi MA, Queeney KL, Perron DC, Dominguez E, Kebede T, Desino KE, Patel H, Vasudevan A.

Bioorg Med Chem Lett. 2016 May 1;26(9):2297-302. doi: 10.1016/j.bmcl.2016.03.043. Epub 2016 Mar 14.

PMID:
27020302
9.

Creation of a S1P Lyase bacterial surrogate for structure-based drug design.

Argiriadi MA, Banach D, Radziejewska E, Marchie S, DiMauro J, Dinges J, Dominguez E, Hutchins C, Judge RA, Queeney K, Wallace G, Harris CM.

Bioorg Med Chem Lett. 2016 May 1;26(9):2293-6. doi: 10.1016/j.bmcl.2016.02.084. Epub 2016 Mar 3.

PMID:
27013389
10.

Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.

Friedman M, Frank KE, Aguirre A, Argiriadi MA, Davis H, Edmunds JJ, George DM, George JS, Goedken E, Fiamengo B, Hyland D, Li B, Murtaza A, Morytko M, Somal G, Stewart K, Tarcsa E, Van Epps S, Voss J, Wang L, Woller K, Wishart N.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4399-404. doi: 10.1016/j.bmcl.2015.09.020. Epub 2015 Sep 8.

PMID:
26372653
11.

Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.

Goedken ER, Argiriadi MA, Banach DL, Fiamengo BA, Foley SE, Frank KE, George JS, Harris CM, Hobson AD, Ihle DC, Marcotte D, Merta PJ, Michalak ME, Murdock SE, Tomlinson MJ, Voss JW.

J Biol Chem. 2015 Feb 20;290(8):4573-89. doi: 10.1074/jbc.M114.595181. Epub 2014 Dec 31.

12.

Optimized protein kinase Cθ (PKCθ) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.

George DM, Breinlinger EC, Argiriadi MA, Zhang Y, Wang J, Bansal-Pakala P, Duignan DB, Honore P, Lang Q, Mittelstadt S, Rundell L, Schwartz A, Sun J, Edmunds JJ.

J Med Chem. 2015 Jan 8;58(1):333-46. doi: 10.1021/jm5013006. Epub 2014 Oct 9.

PMID:
25254961
13.

Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.

George DM, Breinlinger EC, Friedman M, Zhang Y, Wang J, Argiriadi M, Bansal-Pakala P, Barth M, Duignan DB, Honore P, Lang Q, Mittelstadt S, Potin D, Rundell L, Edmunds JJ.

J Med Chem. 2015 Jan 8;58(1):222-36. doi: 10.1021/jm500669m. Epub 2014 Jul 7.

PMID:
25000588
14.

Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor.

Argiriadi MA, Goedken ER, Banach D, Borhani DW, Burchat A, Dixon RW, Marcotte D, Overmeyer G, Pivorunas V, Sadhukhan R, Sousa S, Moore NS, Tomlinson M, Voss J, Wang L, Wishart N, Woller K, Talanian RV.

BMC Struct Biol. 2012 Sep 20;12:22. doi: 10.1186/1472-6807-12-22.

15.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Comess KM, Sun C, Abad-Zapatero C, Goedken ER, Gum RJ, Borhani DW, Argiriadi M, Groebe DR, Jia Y, Clampit JE, Haasch DL, Smith HT, Wang S, Song D, Coen ML, Cloutier TE, Tang H, Cheng X, Quinn C, Liu B, Xin Z, Liu G, Fry EH, Stoll V, Ng TI, Banach D, Marcotte D, Burns DJ, Calderwood DJ, Hajduk PJ.

ACS Chem Biol. 2011 Mar 18;6(3):234-44. doi: 10.1021/cb1002619. Epub 2011 Jan 20.

PMID:
21090814
16.

2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.

Harris CM, Ericsson AM, Argiriadi MA, Barberis C, Borhani DW, Burchat A, Calderwood DJ, Cunha GA, Dixon RW, Frank KE, Johnson EF, Kamens J, Kwak S, Li B, Mullen KD, Perron DC, Wang L, Wishart N, Wu X, Zhang X, Zmetra TR, Talanian RV.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):334-7. doi: 10.1016/j.bmcl.2009.10.103. Epub 2009 Oct 29.

PMID:
19926477
17.

2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.

Argiriadi MA, Ericsson AM, Harris CM, Banach DL, Borhani DW, Calderwood DJ, Demers MD, Dimauro J, Dixon RW, Hardman J, Kwak S, Li B, Mankovich JA, Marcotte D, Mullen KD, Ni B, Pietras M, Sadhukhan R, Sousa S, Tomlinson MJ, Wang L, Xiang T, Talanian RV.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):330-3. doi: 10.1016/j.bmcl.2009.10.102. Epub 2009 Oct 29.

PMID:
19919896
18.

Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18.

Argiriadi MA, Xiang T, Wu C, Ghayur T, Borhani DW.

J Biol Chem. 2009 Sep 4;284(36):24478-89. doi: 10.1074/jbc.M109.023887. Epub 2009 Jun 24.

19.

Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study.

Argiriadi MA, Sousa S, Banach D, Marcotte D, Xiang T, Tomlinson MJ, Demers M, Harris C, Kwak S, Hardman J, Pietras M, Quinn L, DiMauro J, Ni B, Mankovich J, Borhani DW, Talanian RV, Sadhukhan R.

BMC Struct Biol. 2009 Mar 18;9:16. doi: 10.1186/1472-6807-9-16.

20.

Discovery of thieno[2,3-c]pyridines as potent COT inhibitors.

George D, Friedman M, Allen H, Argiriadi M, Barberis C, Bischoff A, Clabbers A, Cusack K, Dixon R, Fix-Stenzel S, Gordon T, Janssen B, Jia Y, Moskey M, Quinn C, Salmeron JA, Wishart N, Woller K, Yu Z.

Bioorg Med Chem Lett. 2008 Sep 15;18(18):4952-5. doi: 10.1016/j.bmcl.2008.08.037. Epub 2008 Aug 14.

PMID:
18755587
21.

Crystal structure of a DNA polymerase sliding clamp from a Gram-positive bacterium.

Argiriadi MA, Goedken ER, Bruck I, O'Donnell M, Kuriyan J.

BMC Struct Biol. 2006 Jan 10;6:2.

22.

Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase.

Yamada T, Morisseau C, Maxwell JE, Argiriadi MA, Christianson DW, Hammock BD.

J Biol Chem. 2000 Jul 28;275(30):23082-8.

23.

Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation.

Argiriadi MA, Morisseau C, Goodrow MH, Dowdy DL, Hammock BD, Christianson DW.

J Biol Chem. 2000 May 19;275(20):15265-70.

24.

Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase.

Argiriadi MA, Morisseau C, Hammock BD, Christianson DW.

Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10637-42.

Supplemental Content

Loading ...
Support Center